Cibc Asset Management Inc Nektar Therapeutics Transaction History

Cibc Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$2.03 - $4.28 $3,223 - $6,796	-1,588 Reduced 9.97%	14,333 $32,000
Q2 2022 Aug 09, 2022	SELL	$3.17 - $6.17 $1,797 - $3,498	-567 Reduced 3.44%	15,921 $60,000
Q4 2021 Feb 08, 2022	BUY	$10.83 - $18.41 $178,565 - $303,544	16,488 New	16,488 $223,000
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $222,687 - $324,419	-14,032 Closed	0 $0
Q3 2019 Oct 30, 2019	SELL	$16.91 - $36.27 $456 - $979	-27 Reduced 0.19%	14,032 $256,000
Q2 2019 Aug 05, 2019	BUY	$31.0 - $36.3 $12,493 - $14,628	403 Added 2.95%	14,059 $500,000
Q1 2019 May 06, 2019	SELL	$31.58 - $46.35 $6,126 - $8,991	-194 Reduced 1.4%	13,656 $459,000
Q4 2018 Feb 12, 2019	BUY	$30.43 - $56.65 $1,156 - $2,152	38 Added 0.28%	13,850 $455,000
Q3 2018 Nov 02, 2018	SELL	$46.46 - $68.49 $4,785 - $7,054	-103 Reduced 0.74%	13,812 $842,000
Q2 2018 Aug 09, 2018	BUY	$46.25 - $104.45 $26,871 - $60,685	581 Added 4.36%	13,915 $679,000
Q1 2018 Apr 30, 2018	BUY	$57.4 - $108.44 $454,550 - $858,736	7,919 Added 146.24%	13,334 $1.42 Million
Q4 2017 Feb 02, 2018	SELL	$23.02 - $60.5 $134,091 - $352,412	-5,825 Reduced 51.82%	5,415 $323,000
Q3 2017 Nov 06, 2017	BUY	$17.79 - $24.0 $199,959 - $269,760	11,240	11,240 $270,000

153

131M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $154M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.